Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Heart Test Laboratories Inc. Warrant (HSCSW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/07/2025: HSCSW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -32.73% | Avg. Invested days 13 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/07/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 2.58 | 52 Weeks Range 0.04 - 0.17 | Updated Date 03/20/2025 |
52 Weeks Range 0.04 - 0.17 | Updated Date 03/20/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.09 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -62.95% | Return on Equity (TTM) -163.47% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 995735 |
Shares Outstanding - | Shares Floating 995735 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Heart Test Laboratories Inc. Warrant
Company Overview
History and Background
Heart Test Laboratories, Inc., doing business as MyoCardia Labs, is a medical technology company focused on developing and commercializing a new, non-invasive approach to cardiac risk assessment. The warrants are derivative securities of the underlying common stock.
Core Business Areas
- Cardiac Risk Assessment Technology: Developing and commercializing MyoCardia Labsu2019 MyoCardia device and associated software for non-invasive cardiac risk assessment. This is their core focus.
Leadership and Structure
Information about the specific leadership team and detailed organizational structure of Heart Test Laboratories Inc. Warrant is not widely available and may be linked to the parent company, Heart Test Laboratories, Inc. generally.
Top Products and Market Share
Key Offerings
- MyoCardia Device (Potential): The MyoCardia device aims to provide a non-invasive method for detecting heart conditions, potentially competing with traditional ECGs and stress tests. Market share is currently negligible as it is still in development/early commercialization. Competitors include GE Healthcare, Philips, and Siemens Healthineers.
Market Dynamics
Industry Overview
The cardiac diagnostic market is large and growing, driven by an aging population and increasing prevalence of heart disease. The industry is dominated by established players offering various diagnostic solutions.
Positioning
Heart Test Laboratories Inc. Warrant, as a derivative of Heart Test Laboratories, Inc., aims to disrupt the market with its non-invasive MyoCardia technology. Success depends on regulatory approvals, clinical validation, and market adoption.
Total Addressable Market (TAM)
The global cardiac diagnostic market is estimated to be in the tens of billions of dollars. Heart Test Laboratories, Inc. aims to capture a portion of this market with its MyoCardia technology, targeting a segment of patients seeking non-invasive cardiac assessment.
Upturn SWOT Analysis
Strengths
- Non-invasive technology
- Potential for early heart disease detection
- Novel approach to cardiac risk assessment
Weaknesses
- Limited commercialization to date
- Dependence on regulatory approvals
- Significant competition from established players
- Lack of robust clinical data
Opportunities
- Partnerships with healthcare providers
- Expansion into new markets
- Development of new applications for MyoCardia technology
- Increasing awareness of non-invasive cardiac testing
Threats
- Regulatory hurdles
- Competition from established diagnostic methods
- Technological obsolescence
- Lack of market acceptance
Competitors and Market Share
Key Competitors
- GE (GE)
- Philips (PHG)
- Siemens Healthineers (SIE.DE)
Competitive Landscape
Heart Test Laboratories Inc. warrants, as a derivative, benefit if the underlying stock performs well. This depends on the success of MyoCardia, which needs to overcome established competitors and gain market acceptance.
Growth Trajectory and Initiatives
Historical Growth: Limited historical growth as the company is in the early stages of commercialization.
Future Projections: Future growth is highly dependent on the successful commercialization and adoption of the MyoCardia technology. Analyst projections may be available for the underlying stock.
Recent Initiatives: Recent initiatives likely focus on securing regulatory approvals, conducting clinical trials, and establishing partnerships.
Summary
Heart Test Laboratories Inc. warrants represent a high-risk, high-reward investment. The success of the warrants is contingent on the success of the MyoCardia technology, which faces significant competition and regulatory hurdles. The company is in its early stages and lacks a proven track record. The warrants offer leveraged exposure to the potential upside but also amplify the downside risk if the company fails to execute its strategy. Investors should carefully consider their risk tolerance before investing.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Market research reports
- Financial news sources
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investors should conduct their own due diligence before making any investment decisions. The information provided is for informational purposes only and does not constitute a recommendation to buy, sell, or hold any securities. Market share data is approximate and based on available industry reports and estimates.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Heart Test Laboratories Inc. Warrant
Exchange NASDAQ | Headquaters Southlake, TX, United States | ||
IPO Launch date 2022-06-15 | CEO, President & Chairman of the Board of Directors Mr. Andrew Simpson | ||
Sector Healthcare | Industry Medical Devices | Full time employees 15 | Website https://heartsciences.com |
Full time employees 15 | Website https://heartsciences.com | ||
HeartSciences Inc., a medical technology company, focuses on applying AI-based technology to an ECG to enhance its clinical utility. It is developing artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction caused by heart disease and/or age-related cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction and conventional ECG information in the same test; and MyoVista Insights, a cloud-based platform to host AI-ECG algorithms on an ECG hardware agnostic basis. The company was formerly known as Heart Test Laboratories, Inc. and changed its name to HeartSciences Inc. in October 2024. HeartSciences Inc. was incorporated in 2007 and is headquartered in Southlake, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.